Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlonstobart + Chemoradiotherapy in Locally Advanced Cervical Cancer
NCT07776821Phase 4Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of PBI-1308 in Cervical Cancer (CC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate up to 3 years. Started Sep 2025; status: recruiting.
02
Drugs
PBI-1308
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07776821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776821.